OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
3.970
+0.060 (1.53%)
At close: Dec 20, 2024, 4:00 PM
3.790
-0.180 (-4.53%)
After-hours: Dec 20, 2024, 7:20 PM EST
OS Therapies Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
84.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOSTX News
- 5 weeks ago - OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - OS Therapies to Present at The Spartan Capital Investor Conference - Business Wire
- 7 weeks ago - Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30 - Business Wire
- 7 weeks ago - OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors - Business Wire
- 2 months ago - OS Therapies to Present at the LD Micro Main Event XVII - Business Wire
- 2 months ago - OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - Business Wire
- 2 months ago - OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit - Business Wire
- 3 months ago - OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates - Business Wire